Eiger Biopharmaceuticals Inc (NASDAQ:EIGR) has received an average rating of “Buy” from the nine research firms that are currently covering the stock, Marketbeat Ratings reports. One investment analyst has rated the stock with a hold recommendation, seven have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month price target among analysts that have covered the stock in the last year is $28.67.
A number of brokerages have weighed in on EIGR. ValuEngine raised Eiger Biopharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, July 2nd. Citigroup began coverage on Eiger Biopharmaceuticals in a research report on Wednesday, June 26th. They issued a “buy” rating and a $22.00 target price for the company. LADENBURG THALM/SH SH reissued a “buy” rating and issued a $28.00 target price on shares of Eiger Biopharmaceuticals in a research report on Monday, August 12th. KeyCorp initiated coverage on shares of Eiger Biopharmaceuticals in a research report on Wednesday, June 26th. They set an “overweight” rating and a $10.72 price target for the company. Finally, Zacks Investment Research raised shares of Eiger Biopharmaceuticals from a “hold” rating to a “buy” rating and set a $11.00 price target for the company in a research report on Tuesday, August 13th.
A number of hedge funds have recently bought and sold shares of the business. BlackRock Inc. boosted its stake in Eiger Biopharmaceuticals by 281.9% in the 2nd quarter. BlackRock Inc. now owns 1,729,161 shares of the biotechnology company’s stock worth $18,330,000 after purchasing an additional 1,276,408 shares during the period. Cormorant Asset Management LP bought a new position in Eiger Biopharmaceuticals in the 2nd quarter worth approximately $12,190,000. Vanguard Group Inc. boosted its stake in Eiger Biopharmaceuticals by 39.0% in the 2nd quarter. Vanguard Group Inc. now owns 1,070,914 shares of the biotechnology company’s stock worth $11,352,000 after purchasing an additional 300,279 shares during the period. Farallon Capital Management LLC bought a new position in Eiger Biopharmaceuticals in the 2nd quarter worth approximately $10,600,000. Finally, Citadel Advisors LLC bought a new position in Eiger Biopharmaceuticals in the 2nd quarter worth approximately $3,168,000. Institutional investors and hedge funds own 84.67% of the company’s stock.
Shares of EIGR traded down $0.54 during trading hours on Thursday, hitting $10.08. The company had a trading volume of 144,550 shares, compared to its average volume of 159,067. The firm has a fifty day moving average price of $10.85 and a 200-day moving average price of $11.03. The company has a debt-to-equity ratio of 0.36, a quick ratio of 9.64 and a current ratio of 9.64. The stock has a market capitalization of $251.59 million, a price-to-earnings ratio of -2.64 and a beta of 1.02. Eiger Biopharmaceuticals has a 52-week low of $8.40 and a 52-week high of $15.33.
Eiger Biopharmaceuticals (NASDAQ:EIGR) last issued its earnings results on Thursday, August 8th. The biotechnology company reported ($0.75) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.73) by ($0.02). Research analysts anticipate that Eiger Biopharmaceuticals will post -2.51 earnings per share for the current fiscal year.
About Eiger Biopharmaceuticals
Eiger BioPharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare diseases in the United States and internationally. The company's lead program is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trial for treating hepatitis delta virus (HDV) infection.
Recommended Story: Front-End Load
Receive News & Ratings for Eiger Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eiger Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.